Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
Grant supports adding new tech to cancer research for faster progress. Applicants must use NCI-supported tech to enhance current projects for better outcomes.
Browse similar grants
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: April 4, 2025 | October 3, 2025 | December 9, 2025 (final closing date)
Funding Amounts: Up to $150,000 direct costs/year, max 2 years; estimated total program funding $700,000; ~3 awards expected.
Summary: Supports revision applications to active NCI U01 projects to incorporate and validate novel technologies developed via the NCI IMAT program to accelerate cancer research.
Key Information: Only currently funded NCI U01 projects eligible; technology must be IMAT-supported and not developed by the parent U01 PI.
Description
This funding opportunity supports revision applications to existing, active NCI U01 research projects. The aim is to accelerate or expand the parent project by incorporating a new technical approach or device that was developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program. The program incentivizes independent validation and broader adoption of emerging technologies for cancer research, fostering interdisciplinary collaboration and advancing innovative tools and methods in the field.
Proposals must specifically address how the integration of the IMAT-supported technology will enhance the ongoing research and provide value to the broader cancer research community. Projects that seek to incorporate commercially available or non-IMAT-developed technologies, or those led by the technology's original developer, are not eligible.
